Autopsy report · NCT03780543
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 2 years 4 months before it stopped.
- 92 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Assembly Biosciences
- Sponsor type
- Industry
- Conditions
- Chronic Hepatitis B
- Interventions
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Participants
- 92
- Sites
- 24
- Countries
- Canada, Hong Kong, New Zealand, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.